ACR 2021
axPsA is axSpA is not...!?
Abstract: 1811
high5immunology.tv | Rheumatology | ACR 2021
This information is brought to you by high5immunology.TV and is not sponsored by, nor a part of, the American College of Rheumatology.
DISCOVER 1&2, PSUMMIT
ACR 2021
axPsA is axSpA is not...!?
TitAIN
ACR 2021
New treatment alternative in GCA: promising secukinumab…
MUST
ACR 2021
No need for methotrexate in ustekinumab treatment in…
SPIRIT-H2H
ACR 2021
IL-17 pathway important for pain in PsA
ARIAA
ACR 2021
ARIAA: prevention study or very early treatment of RA?
ORAL Surveillance
ACR 2021
Dear Doctor: JAKi risk factors and safety profile - is…
TRAIL1
ACR 2021
Pulmonary involvement and possible therapy concepts in…
N3C, REDO
ACR 2021
Should we use ultra-low-dose rituximab during the…
ORAL Surveillance
ACR 2021
Long awaited - MACE data from ORAL surveillance
ARIAA
ACR 2021
Abatacept may reduce subclinical inflammation in RA-at…
ORAL Surveillance
ACR 2021
Tofacitinib is associated with a slightly increased…
RAMS
ACR 2021
Nausea & alopecia with MTX in RA
JAK-pot
ACR 2021
Cycling JAKi compared to switching to biologic DMARD in…
ORAL Surveillance, National VA registry (U.S.)
ACR 2021
Cardiovascular disease in RA
ACR 2021
We need predictors of response for RA treatment
ACR 2021
Statins reduce cardiovascular risk and mortality -…
ACR 2021
Discordance between patients and physicians in RA
RAMS
ACR 2021
Quels effets indésirables peuvent être associés à la…
ORAL Surveillance
ACR 2021
Tofacitinid se asocia con un ligero incremento del…
ARIAA
ACR 2021
Abatacept reduce la inflamación subclínica en pacientes…
JAK-pot
ACR 2021
Skifte mellom JAK hemmere sammenliknet med skifte til…
ORAL Surveillance
ACR 2021
Lange erwartet - MACE-Daten zur ORAL Surveillance
ACR 2021
Quels marqueurs de réponse aux traitements dans la…
ACR 2021
Las estatinas reducen el riesgo cardiovascular y la…
ACR 2021
Désaccords patient/Médecin : se comprendre pour plus…
SELECT-PsA 1
ACR 2021
Comparison of composit indices for disease activity in…
ACR 2021
PET/CT in diagnosis for PsA
ACR 2021
Secukinumab vs TNF-α blockers in enthesitis
ACR 2021
Prediction of psoriatic arthritis in patients with…
DISCOVER 1&2, PSUMMIT
ACR 2021
Guselkumab: the better ustekinumab?!
MAXIMISE
ACR 2021
Axial PsA MRI data
ACR 2021
Joint effusions and enthesitis after physical exertion
MUST
ACR 2021
No need for MTX in ustekinumab-treated patients
ACR 2021
Tildrakizumab in PsA
DISCOVER 1&2
ACR 2021
Guselkumab in axial symptoms
ACR 2021
Association of C-reactive protein and non-steroidal…
Select PsA 1 und 2
ACR 2021
Upadacitinib in PsA
ACR 2021
Osteoporosis in PsA
SPIRIT-H2H
ACR 2021
Pain differs: Superior effect of IL-17-inhibition vs.…
DISCOVER 1&2
ACR 20221
Anemia is an issue in PsA - proper treatment possible!
MUST
ACR 2021
Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab
ACR 2021
Osteoporose bei PsA
ACR 2021
Gelenkergüsse und Enthesitis nach körperlicher…
ACR 2021
Secukinumab vs TNF-α Blocker bei Enthesitis
ACR 2021
Associazione di livelli di PCR e uso di FANS con gli…
DISCOVER 1&2, PSUMMIT
ACR 2021
Guselkumab: das bessere Ustekinumab?!
Select PsA 1 und 2
ACR 2021
Upadacitinib bei PsA
SPIRIT-H2H
ACR 2021
Schmerz ist nicht gleich Schmerz: Unterschied von…
ACR 2021
Previsione di sviluppo di artrite psoriasica in…
SELECT-PsA 1
ACR 2021
Studio di confronto tra i vari indici compositi per la…
ACR 2021
Tildrakizumab bei PsA
MAXIMISE
ACR 2021
Datos de RM en APs axial
ACR 2021
PET-CT zur Quantifizierung der Entzündung
DISCOVER 1&2
ACR 2021
Anämie bei PsA ist ein Thema - effektive Therapie…
DISCOVER 1&2
ACR 2021
Guselkumab bei axialer Symptomatik
SELECT-AXIS 1
ACR 2021
JAK inhibitors - new kids on the block
ACR 2021
Self-monitoring of disease activity with a smartphone…
ACR 2021
Dose tapering of TNF inhibitors in axSpA
MAXIMISE
ACR 2021
Axial PsA MRI data
ACR 2021
Optimización de iTNF en EspAax
MAXIMISE
ACR 2021
Datos de RM en APs axial
ACR 2021
l’auto-monitoraggio di malattia è fattibile nella…
SELECT-AXIS 1
ACR 2021
Inhibidores JAK: nuevas dianas en EspAax
BLISS-BELIEVE
ACR 2021
Not yet a new standard: belimumab + rituximab
ACR 2021
JAKi baricitinib successfully mastered phase II study
ACR 2021
JAK-Inhibitor Baricitinib in Phase II erfolgreich
BLISS-BELIEVE
ACR 2021
Kombination Belimumab und Rituximab noch kein neuer…
TitAIN
ACR 2021
Secukinumab in giant cell arteritis
ACR 2021
Baricitinib in relapsing giant cell arteritis
ACR 2021
PET as a predictor of vascular damage in large-vessel…
TitAIN
ACR 2021
A new therapeutic approach for giant cell arteritis?
ACR 2021
Il ruolo della PET nel predire il danno vascolare nelle…
TitAIN
ACR 2021
Neuer Therapieansatz für die Riesenzellarteriitis?
ACR 2021
Baricitinib nell'arterite a cellule giganti recidivante
TitAIN
ACR 2021
Secukinumab nell'arterite a cellule giganti
N3C Registry
ACR 2021
Breakthrough infections after SARS-CoV2-vaccination -…
ACR 2021
Anticytokine antibodies causing severe microbacterial…
ACR 2021
Immune responses to COVID-19 vaccines
ACR 2021
Booster with which one if there is no seroconversion?
N3C, REDO
ACR 2021
Should we use ultra-low-dose rituximab during the…
ACR 2021
Analysis of COVID-19 infection among vaccinated…
ACR 2021
Impact of COVID-19 on patients with rheumatic diseases
ACR 2021
Vaccination against Delta variant worse in patients…
SCQM Registry
ACR 2021
TNF blockers reduce the antibody response to RNA…
COVID-19 Global Rheumatology Alliance registry
ACR 2021
Breakthrough infections after SARS-CoV2-vaccination -…
ACR 2021
Womit boostern bei fehlender Serokonversion?
SCQM Register
ACR 2021
TNF-Blocker reduzieren Antikörperantwort bei…
COVID-19 Global Rheumatology Alliance registry
ACR 2021
Durchbruchsinfektionen nach SARS-CoV2-Impfung -…
ACR 2021
Schlechtere Neutralisation der Delta-Variante unter…
N3C Register
ACR 2021
Durchbruchsinfektionen nach SARS-CoV2-Impfung -…
ACR 2021
Immunresponser til COVID-19 vaksiner
NOR-DRUM B
ACR 2021
Therapeutic drug monitoring - a randomized controlled…
ACR 2021
Pearls and myths in rheumatology
ACR 2021
CBD - an alternative therapy for chronic pain
ACR 2021
Skin findings in patients of color with rheumatic…
VITAL
ACR 2021
New exciting data - dietary supplements with vitamin D…
COMPACT
ACR 2021
PROs from a real-world study on etanercept biosimilar -…
VITAL
ACR 2021
Neue spannende Daten - Nahrungsergänzung mit Vitamin D…
NOR-DRUM B
ACR 2021
Monitorering av legemiddelkonsentrasjoner (Therapeutic…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!